Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules

  title={Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules},
  author={S. Peltier and J M Oger and Fr{\'e}d{\'e}ric Lagarce and William Couet and Jean Pierre Benoit},
  journal={Pharmaceutical Research},
PurposeThe aim of this study was to evaluate the pharmacokinetics of paclitaxel-loaded lipid nanocapsules (LNC) in rats to assess the intrinsic effect of the dosage form on the improvement of paclitaxel oral exposure.MethodsPaclitaxel-loaded LNC were prepared and characterized in terms of size distribution, drug payload, and the kinetics of paclitaxel crystallization. Taxol®, Taxol® with verapamil, or paclitaxel-loaded LNC were administered orally to rats. The plasma concentration of paclitaxel… 

Development of Lipid-Based Nanoparticles for Enhancing the Oral Bioavailability of Paclitaxel

PTX-SLNs dispersed in an aqueous environment are promising novel formulations that enhanced the oral bioavailability of hydrophobic drugs, like paclitaxel and were quite safe for oral delivery of pac litaxel as observed by in vivo toxicity studies.

In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.

This study highlights the importance of efficacy studies paired to pharmacokinetic studies for nanomedicines and concludes that despite good absorption, (DSPE-PEG-NH2) LNCs failed to remain efficient after oral route.

Pharmacokinetics and antitumor efficacy of paclitaxel-cyclodextrin complexes loaded in mucus-penetrating nanoparticles for oral administration.

PTX orally administered in poly(anhydride) NPs, combined with cyclodextrins and poly(ethylene glycol), displayed sustained plasma levels and significant antitumor effect in a syngenic tumor model of carcinoma in mice.

Biodistribution and in vivo performance of fattigation-platform theranostic nanoparticles.

Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies.

The present proof-of-concept experimental data proved that the formulation of vitamin E TPGS emulsified PLGA NPs is a promising approach for paclitaxel oral administration.

Enhanced Oral Delivery of Docetaxel Using Thiolated Chitosan Nanoparticles: Preparation, In Vitro and In Vivo Studies

The nanoparticles prepared in this study showed promising results for the development of an oral drug delivery system for anticancer drugs.

Improving Efficacy, Oral Bioavailability, and Delivery of Paclitaxel Using Protein-Grafted Solid Lipid Nanoparticles.

WGA-conjugated, PTX-loaded solid lipid nanoparticles (LPSN) exhibited enhanced anticancer activity against A549 lung cancer cells after internalization through lectin receptors than free PTX, which could be due to cumulative bioadhesive property of the nanocarrier system and the targeting ligand WGA.

Niosomes encapsulating paclitaxel for oral bioavailability enhancement: preparation, characterization, pharmacokinetics and biodistribution

The high PCT accumulation in intestine and liver obtained after Carbopol 974P coated niosomes administration indicated their potential regarding effective treatment of localized carcinomas in intestinal and liver.

Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles.




Enhanced Oral Absorption of Paclitaxel in a Novel Self-Microemulsifying Drug Delivery System with or Without Concomitant Use of P-Glycoprotein Inhibitors

The results indicate that SMEDDS is a promising novel formulation to enhance the oral bioavailability of paclitaxel, especially when coadministered with a suitable P-gp inhibitor, such as CsA.

Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin.

  • Jun-shik ChoiB. JoYoun-Chul Kim
  • Biology, Chemistry
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
  • 2004

Formulating Paclitaxel in Nanoparticles Alters Its Disposition

These data indicate that formulation of paclitaxel affects its clearance and distribution into tissues, with preferential accumulation of nanoparticles in the liver, spleen, small intestine, and kidney.

A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.

  • L. MuS. Feng
  • Materials Science
    Journal of controlled release : official journal of the Controlled Release Society
  • 2003

Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers.

The paclitaxel plasma and LP distribution profile for PMT was similar to the distribution profile of TAX, suggesting that the plasma andLP distribution of pac litaxel is independent of the method of pac Litaxel delivery and that LP distribution is not a function of mass lipid levels.

In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits

The significant increases in anti–factor Xa activity and aPTT confirmed the oral absorption in rabbits of heparin released from polymeric NPs.

Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

Coadministration of oral CsA increased the systemic exposure of oral paclitaxel from negligible to therapeutic levels, and the combination enables treatment with oral pac litaxel.

Enhanced Oral Bioavailability of Paclitaxel by Coadministration of the P-Glycoprotein Inhibitor KR30031

The findings suggest that about 54% of a paclitaxel oral dose is extruded to the gut lumen by P-glycoprotein, which indicates that the bioavailability of pac litaxel could be enhanced by coadministration of a P- glycoprotein inhibitor, KR-30031.

Oral Delivery of Taxanes

The feasibility of oral administration of paclitaxel and docetaxel in cancer patients was recently demonstrated and the safety of the oralroute for both taxanes is good.

Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

GF120918 at this dose-level selectively and completely blocks P-glycoprotein in the intestines and does not notably interfere in the elimination of paclitaxel by metabolism or other transporters, indicating that this compound is suitable for chronic use in cancer patients.